FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896778092> ?p ?o ?g. }

• W2896778092 endingPage "e27" @default.
• W2896778092 startingPage "e27" @default.
• W2896778092 abstract "The mammalian target of rapamycin (mTOR) signaling has been implicated in esophageal cancer progression. Preclinical studies have shown synergy between everolimus, an mTOR inhibitor, radiation, and platinum agents. Preclinical data suggested that Aurora Kinase A (AURKA) plays an important role in the development of everolimus resistance and that this is mediated through upregulation of c-MYC. We postulated that patients with persistent disease at time of surgery after neoadjuvant therapy would have higher levels of both AURKA and c-MYC. We conducted a multi-institutional phase IB trial to determine the recommended phase II dose of concurrent everolimus with carboplatin and radiation in patients with localized esophageal cancer. Patients with Stage II/III esophageal cancer and ECOG performance status 0-1 were enrolled. Following two cycles of induction Capecitabine/Oxaliplatin (XELOX), patients were restaged and those without evidence of disease progression, received radiation to a total dose of 50.4 Gy in 28 fractions with concurrent weekly carboplatin (AUC=2), with escalating doses of everolimus. A standard 3+3 dose escalation design was used. The recommended phase II dose of everolimus with concurrent weekly carboplatin and radiation was determined to be 2.5 mg QOD. Paraffin-embedded tissue blocks from the surgical specimen were used for immunohistochemical analysis for AURKA and c-MYC and levels of these markers were correlated with pathologic response. Nineteen patients were enrolled. There were two screen failures (thrombocytopenia, metastases) and four patients were removed from study due to poor tolerance of XELOX (n = 2) or disease progression (n = 2). Thirteen patients completed concurrent chemoradiation therapy and were deemed resectable. All patients had adenocarcinoma, median age was 58 and 85% were males. All patients achieved an R0 resection with a pathologic response rate of 40% and a pathologic complete response rate of 23%. The 2-year PFS and OS were 50% and 49.6%, respectively. Only 6 of the 13 patients had tissue available for biomarker analysis. All 6 patients had viable disease on final pathologic assessment suggesting resistance to everolimus. Five patients with high levels of AURKA also had high levels of c-MYC expression (83%). The one patient with low level of AURKA also had low levels of c-MYC expression (16%). Biomarker studies from this Phase IB trial suggest that AURKA is associated with c-MYC dependent resistance to mTOR inhibition. Targeting AURKA may be a novel therapeutic strategy that can be used in everolimus-resistant tumors that show overexpression of AURKA." @default.
• W2896778092 created "2018-10-26" @default.
• W2896778092 creator A5000476372 @default.
• W2896778092 creator A5001099941 @default.
• W2896778092 creator A5007905070 @default.
• W2896778092 creator A5010469485 @default.
• W2896778092 creator A5023126483 @default.
• W2896778092 creator A5025524746 @default.
• W2896778092 creator A5032311798 @default.
• W2896778092 creator A5036053620 @default.
• W2896778092 creator A5036672833 @default.
• W2896778092 creator A5043235685 @default.
• W2896778092 creator A5045720980 @default.
• W2896778092 creator A5046023287 @default.
• W2896778092 creator A5046360681 @default.
• W2896778092 creator A5047032605 @default.
• W2896778092 creator A5051015072 @default.
• W2896778092 creator A5052557829 @default.
• W2896778092 creator A5052955777 @default.
• W2896778092 creator A5065088834 @default.
• W2896778092 creator A5068160040 @default.
• W2896778092 creator A5074298815 @default.
• W2896778092 creator A5082618622 @default.
• W2896778092 creator A5082875185 @default.
• W2896778092 creator A5088705122 @default.
• W2896778092 date "2018-11-01" @default.
• W2896778092 modified "2023-10-18" @default.
• W2896778092 title "Pilot Study of Potential Activation of c-MYC by Aurora Kinase A in Everolimus-Resistant Localized Esophageal Cancer Treated with XELOX followed by Carboplatin/Radiation" @default.
• W2896778092 doi "https://doi.org/10.1016/j.ijrobp.2018.07.510" @default.
• W2896778092 hasPublicationYear "2018" @default.
• W2896778092 type Work @default.
• W2896778092 sameAs 2896778092 @default.
• W2896778092 citedByCount "0" @default.
• W2896778092 crossrefType "journal-article" @default.
• W2896778092 hasAuthorship W2896778092A5000476372 @default.
• W2896778092 hasAuthorship W2896778092A5001099941 @default.
• W2896778092 hasAuthorship W2896778092A5007905070 @default.
• W2896778092 hasAuthorship W2896778092A5010469485 @default.
• W2896778092 hasAuthorship W2896778092A5023126483 @default.
• W2896778092 hasAuthorship W2896778092A5025524746 @default.
• W2896778092 hasAuthorship W2896778092A5032311798 @default.
• W2896778092 hasAuthorship W2896778092A5036053620 @default.
• W2896778092 hasAuthorship W2896778092A5036672833 @default.
• W2896778092 hasAuthorship W2896778092A5043235685 @default.
• W2896778092 hasAuthorship W2896778092A5045720980 @default.
• W2896778092 hasAuthorship W2896778092A5046023287 @default.
• W2896778092 hasAuthorship W2896778092A5046360681 @default.
• W2896778092 hasAuthorship W2896778092A5047032605 @default.
• W2896778092 hasAuthorship W2896778092A5051015072 @default.
• W2896778092 hasAuthorship W2896778092A5052557829 @default.
• W2896778092 hasAuthorship W2896778092A5052955777 @default.
• W2896778092 hasAuthorship W2896778092A5065088834 @default.
• W2896778092 hasAuthorship W2896778092A5068160040 @default.
• W2896778092 hasAuthorship W2896778092A5074298815 @default.
• W2896778092 hasAuthorship W2896778092A5082618622 @default.
• W2896778092 hasAuthorship W2896778092A5082875185 @default.
• W2896778092 hasAuthorship W2896778092A5088705122 @default.
• W2896778092 hasConcept C121608353 @default.
• W2896778092 hasConcept C126322002 @default.
• W2896778092 hasConcept C143998085 @default.
• W2896778092 hasConcept C185592680 @default.
• W2896778092 hasConcept C2776694085 @default.
• W2896778092 hasConcept C2777909004 @default.
• W2896778092 hasConcept C2778239845 @default.
• W2896778092 hasConcept C2779699572 @default.
• W2896778092 hasConcept C2779742542 @default.
• W2896778092 hasConcept C2779984678 @default.
• W2896778092 hasConcept C2780962732 @default.
• W2896778092 hasConcept C2781451048 @default.
• W2896778092 hasConcept C31760486 @default.
• W2896778092 hasConcept C502942594 @default.
• W2896778092 hasConcept C509974204 @default.
• W2896778092 hasConcept C526805850 @default.
• W2896778092 hasConcept C55493867 @default.
• W2896778092 hasConcept C62478195 @default.
• W2896778092 hasConcept C71924100 @default.
• W2896778092 hasConcept C86554907 @default.
• W2896778092 hasConceptScore W2896778092C121608353 @default.
• W2896778092 hasConceptScore W2896778092C126322002 @default.
• W2896778092 hasConceptScore W2896778092C143998085 @default.
• W2896778092 hasConceptScore W2896778092C185592680 @default.
• W2896778092 hasConceptScore W2896778092C2776694085 @default.
• W2896778092 hasConceptScore W2896778092C2777909004 @default.
• W2896778092 hasConceptScore W2896778092C2778239845 @default.
• W2896778092 hasConceptScore W2896778092C2779699572 @default.
• W2896778092 hasConceptScore W2896778092C2779742542 @default.
• W2896778092 hasConceptScore W2896778092C2779984678 @default.
• W2896778092 hasConceptScore W2896778092C2780962732 @default.
• W2896778092 hasConceptScore W2896778092C2781451048 @default.
• W2896778092 hasConceptScore W2896778092C31760486 @default.
• W2896778092 hasConceptScore W2896778092C502942594 @default.
• W2896778092 hasConceptScore W2896778092C509974204 @default.
• W2896778092 hasConceptScore W2896778092C526805850 @default.
• W2896778092 hasConceptScore W2896778092C55493867 @default.
• W2896778092 hasConceptScore W2896778092C62478195 @default.
• W2896778092 hasConceptScore W2896778092C71924100 @default.
• W2896778092 hasConceptScore W2896778092C86554907 @default.
• W2896778092 hasIssue "3" @default.

• next